Literature DB >> 20383893

Update on the treatment options for multiple sclerosis.

Masaaki Niino1, Hidenao Sasaki.   

Abstract

Recent progress in the treatment of multiple sclerosis (MS) is remarkable, and the introduction of new therapies is yielding improvements in the management of MS. Furthermore, clinical trials with many different types of agents, especially selected monoclonal antibodies, have been undertaken or are ongoing, and some of the agents involved will probably be available as treatments for MS in the near future. Although these new and promising agents include targeted immunotherapies, some of them have limitations such as associated severe adverse events and the development of neutralizing antibodies. With regard to risk-benefit ratios, pharmacogenetics could shed light on inherited differences in drug metabolism and response, which would make individualized therapy possible in MS. Here, we review the recent progress in current therapeutic strategies for MS, and the potential options for future MS treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20383893     DOI: 10.1586/eci.09.75

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  7 in total

Review 1.  ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).

Authors:  Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2011-03-16       Impact factor: 4.418

Review 2.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 3.  Therapeutic Yoga: Symptom Management for Multiple Sclerosis.

Authors:  Kim A Rogers; Megan MacDonald
Journal:  J Altern Complement Med       Date:  2015-08-13       Impact factor: 2.579

Review 4.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

5.  Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1.

Authors:  P Fagone; K Mangano; C Quattrocchi; R Motterlini; R Di Marco; G Magro; N Penacho; C C Romao; F Nicoletti
Journal:  Clin Exp Immunol       Date:  2011-01-14       Impact factor: 4.330

6.  A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.

Authors:  R Saccardi; M S Freedman; M P Sormani; H Atkins; D Farge; L M Griffith; G Kraft; G L Mancardi; R Nash; M Pasquini; R Martin; P A Muraro
Journal:  Mult Scler       Date:  2012-03-01       Impact factor: 6.312

Review 7.  Yoga as an intervention to manage multiple sclerosis symptoms.

Authors:  Priyanka Thakur; Ashu Mohammad; Yash Raj Rastogi; Reena V Saini; Adesh K Saini
Journal:  J Ayurveda Integr Med       Date:  2019-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.